Siegfried Holding AG

Swiss Stock Exchange:SFZN.SW

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🔬 Chemicals & Advanced Materials

🌿 Fertilizers

💊 Pharmaceuticals

Location

Switzerland

Market Cap

USD 5.08 B

Share Price

USD 115.10

Avg Daily Volume

90,504

Change (1 day)

-0.33%

Change (1 year)

-89.05%

Change (YTD)

-89.44%

Siegfried Holding AG Revenue for the year ending December 31, 2024: USD 1.43 B

Siegfried Holding AG Revenue is USD 1.43 B for the year ending December 31, 2024, a -5.61% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Siegfried Holding AG Revenue for the year ending December 31, 2023 was USD 1.51 B, a 13.58% change year over year.
Siegfried Holding AG Revenue for the year ending December 31, 2022 was USD 1.33 B, a 10.03% change year over year.
Siegfried Holding AG Revenue for the year ending December 31, 2021 was USD 1.21 B, a 26.59% change year over year.
Siegfried Holding AG Revenue for the year ending December 31, 2020 was USD 954.58 M, a 10.94% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

Swiss Stock Exchange: SFZN.SW

Siegfried Holding AG

CEO	Mr. Marcel Imwinkelried
IPO Date	April 14, 1995
Location	Switzerland
Headquarters	Untere Bruehlstrasse 4
Employees	3,886
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🔬 Chemicals & Advanced Materials 🌿 Fertilizers 💊 Pharmaceuticals

Description

Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.